

## Rana, Pratibha

---

**From:** Rana, Pratibha  
**Sent:** Friday, April 08, 2011 6:56 PM  
**To:** 'Matthew Vaughn'  
**Subject:** STN 125389/0 Information Request II/ April 8 2011

**To: Matthew Vaughn  
Biotest Pharmaceuticals Corporation**

This is regarding your BLA submission STN 125389/0 for Immune Globulin Intravenous (Human), submitted to the Agency on November 3, 2010. FDA continues with the review of the referenced submission and requests BPC to provide the following information.

1. Glycine concentration in Bivigam® is higher than some other IGIV products in the market. Please submit a toxicological assessment on the clinical safety of glycine.
2. How is the “worse case scenario” concentration of (b)(4) for TNBP (report number be-008-91) and TritonX (report number be-009-91) calculated?

Please submit a response to this request as an amendment to the file by May 9, 2011.

Thank you.

Pratibha Rana

Pratibha Rana, M.S.  
Regulatory Project Manager

FDA/CBER/OBRR  
Division of Blood Applications  
1401 Rockville Pike  
Rockville, MD 20852  
Office: (301) 827-6124  
Fax: (301) 827-2857  
email: pratibha.rana@fda.hhs.gov

"THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone."